Immunotherapy Targeting Tumor Neoantigenic Peptides

This technology provides a method for identifying specific biomarkers to discriminate Ewing sarcoma from other tumors, particularly sarcomas. These biomarkers are tumor specific neoantigenic peptides encoded by an unannotated transcript regulated by an aberrant fusion protein (EWS-FL1) with higher expression in Ewing sarcoma. These peptides are highly immunogenic and could lead to tumor-directed immunotherapies, like vaccination, antibodies or cytotoxic T-cell-based therapies.